证券代码：688075 证券简称：安旭生物 公告编号：2025-021 关于召开2025年第一次临时股东大会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 杭州安旭生物科技股份有限公司 重要内容提示： 一、 召开会议的基本情况 （一） 股东大会类型和届次 2025年第一次临时股东大会 （二） 股东大会召集人：董事会 （三） 投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结 合的方式 （四） 现场会议召开的日期、时间和地点 1 召开日期时间：2025 年 8 月 22 日 14 点 00 分 股东大会召开日期：2025年8月22日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 网投票平台的投票时间为股东大会召开当日的 9:15-15:00。 召开地点：浙江省杭州市莫干山路 1418-50 号 4 幢 5 楼大会议室 （五） 网络投票的系统、起止日期和投票时间。 （六） 融资融券、转融通、约定购回业务账户和沪股通投资者的投票程序 网络投票系统：上海证券交易所股东大会网络投票系统 网络 ...

证券代码：688075 证券简称：安旭生物 公告编号：2025-018 杭州安旭生物科技股份有限公司 第二届监事会第十六次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责 一、监事会会议召开情况 杭州安旭生物科技股份有限公司（以下简称"公司"或"安旭生物"）第二届监 事会第十六次会议通知于 2025 年 8 月 1 日以邮件方式发出送达全体监事，会议于 2025 年 8 月 6 日以现场表决方式召开，会议由公司监事会主席张炯先生主持，会 议应到监事 3 人，实到监事 3 人。本次会议的召集、召开符合《中华人民共和国 公司法》等法律、法规、规章、规范性文件和《公司章程》的有关规定，会议形 成的决议合法、有效。 二、监事会会议审议情况 (一)审议通过《关于取消监事会、修订<公司章程>并办理工商变更登记及修 订相关制度的议案》 监事会认为：根据《中华人民共和国公司法》《上市公司治理准则》《上市 公司章程指引》《上海证券交易所科创板股票上市规则》和《上海证券交易所科 创板上市公司自律监管指引第 1 号——规范运作》等法律法 ...

证券代码：688075 证券简称：安旭生物 公告编号：2025-016 杭州安旭生物科技股份有限公司 第二届董事会第十八次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 杭州安旭生物科技股份有限公司（以下简称"公司"或"安旭生物"）第二届董事 会第十八次会议通知于2025年8月1日以邮件方式发出送达全体董事，会议于2025 年 8 月 6 日以现场结合通讯表决方式召开，会议由公司董事长凌世生先生主持，会 议应到董事 7 人，实到董事 7 人。本次会议的召集、召开符合《中华人民共和国公 司法》等法律、法规、规章、规范性文件和《公司章程》的有关规定，会议形成的 决议合法、有效。 二、董事会会议审议情况 （一） 审议通过《关于董事会换届选举暨提名第三届董事会非独立董事候选 人的议案》 本议案尚需提交公司股东大会审议。 1 具体内容详见公司同日在上海证券交易所网站（www.sse.com.cn）披露的公司 《关于董事会换届选举的公告》。 本议案已经董事会提名委员会全体委员审议通过并同意提交董事 ...

Core Viewpoint - Anxu Bio (688075.SH) plans to utilize up to RMB 4 billion of its temporarily idle self-owned funds to purchase low-risk, high-liquidity investment products through qualified financial institutions, with a usage period effective from September 18, 2025, for 12 months [1] Group 1 - The company intends to invest in safe and liquid financial products, including but not limited to principal-protected investment products, structured deposits, large-denomination certificates of deposit, and time deposits [1] - The investment will be executed through banks and securities companies that have legal operating qualifications [1] - The funds can be rolled over within the specified limit and duration [1]

天坛生物直线涨停，科拓生物、南模生物、赛伦生物涨超10%，沃森生物、安旭生物等跟涨。 (本文来自第一财经) ...

MACD金叉信号形成，这些股涨势不错！ 据北京日报，中国疾控中心艾防中心等团队完成我国首个复制型天坛痘苗载体艾滋病疫苗I期临床试 验。该研究创新性采用曾用于消灭天花的"天坛株"痘苗病毒为载体，试验验证了该方案的安全性且能激 发有效免疫反应。这标志着我国在艾滋病疫苗研发领域取得重要进展。 受此影响，A股市场生物医药股拉升，其中，南模生物、赛伦生物涨超14%，天坛生物10CM涨停，之 江生物、沃森生物、仁度生物、安旭生物等跟涨。 ...

Group 1 - The A-share market saw a surge in biopharmaceutical stocks, with notable increases including Nanmo Bio and Sairun Bio rising over 14%, and Tiantan Bio hitting a 10% limit up [1] - The China CDC and other teams completed the first Phase I clinical trial of a replicative Tian Tan smallpox vaccine-based HIV vaccine, marking a significant advancement in HIV vaccine research in China [1] - The innovative approach utilized the "Tian Tan strain" smallpox virus, previously used to eradicate smallpox, to verify the safety and effective immune response of the vaccine [1]

Company Overview - Anxu Bio focuses on the research, development, production, and sales of POCT reagents and instruments [1] - The company has been recognized as a "Zhejiang Province Intellectual Property Demonstration Enterprise" and a "National Intellectual Property Advantage Enterprise" [1] - As of 2024, Anxu Bio has obtained 44 new authorized patents, including 13 invention patents, bringing the total to 305 authorized patents, of which 43 are invention patents [1] Financial Performance - As of the first quarter of 2025, Anxu Bio reported a revenue of 115 million yuan, a year-on-year decrease of 10.90% [1] - The net profit for the same period was approximately 34.03 million yuan, reflecting a year-on-year decline of 51.52% [1] - The company's gross profit margin stands at 42.32% [1] Market Position - Anxu Bio's current price-to-earnings (PE) ratio is 33.53, compared to the industry average of 54.56 and the industry median of 37.54 [2] - The company's total market capitalization is 5.235 billion yuan [1][2] - As of the first quarter of 2025, two institutions hold shares in Anxu Bio, with a total of 172,000 shares valued at 0.07 million yuan [1]

Core Viewpoint - The company announced a cash dividend distribution of 0.8 yuan per share for the fiscal year 2024, totaling approximately 101.67 million yuan for all shareholders [2][4]. Summary by Relevant Sections Dividend Distribution Plan - The profit distribution plan was approved at the annual shareholders' meeting held on May 22, 2025 [2]. - The total share capital before the distribution is 127,082,805 shares, with a total cash dividend of 101,666,244 yuan [4]. Distribution Objects - The cash dividend will be distributed to all shareholders registered with the China Securities Depository and Clearing Corporation Limited Shanghai Branch as of the close of trading on the day before the dividend record date [3]. Implementation Method - The dividends for unrestricted circulating shares will be distributed through the clearing system of the China Securities Depository and Clearing Corporation [4]. - Shareholders who have completed designated trading can receive their cash dividends on the distribution date at their designated securities business department [4]. Taxation on Dividends - For individual shareholders holding unrestricted circulating shares for over one year, the cash dividend of 0.8 yuan per share is exempt from personal income tax [8]. - For shares held for one year or less, the tax will be calculated upon the transfer of shares, with a maximum effective tax rate of 20% for shares held for one month or less [8]. - For limited circulating shares, the tax treatment varies, with a post-tax dividend of 0.72 yuan per share for certain categories of shareholders [9][10]. Contact Information - For inquiries regarding the dividend distribution, shareholders can contact the company's securities department at 0571-85391552 [10].

Core Points - The company announced a cash dividend distribution of 0.8 RMB per share, totaling 101,666,244 RMB based on a total share capital of 127,082,805 shares [1] - The dividend distribution plan was approved at the annual general meeting held on May 22, 2025 [1] - The cash dividend will be distributed to shareholders registered by the end of the trading day on the record date [1] Dividend Distribution Details - The cash dividend of 0.8 RMB per share is inclusive of tax [1] - The distribution will be managed by China Securities Depository and Clearing Corporation Limited, Shanghai Branch [1] - Shareholders who have not completed designated transactions will have their dividends held by the clearing company until the transactions are completed [1] Tax Implications - For individual shareholders holding unrestricted shares for over one year, the dividend income is exempt from individual income tax [3] - For shares held for less than one year, the tax treatment varies: 20% tax for holdings of one month or less, and 10% tax for holdings between one month and one year [3] - For qualified foreign institutional investors (QFII), a 10% corporate income tax will be withheld, resulting in a net dividend of 0.72 RMB per share [5] - Hong Kong investors will also receive a net dividend of 0.72 RMB per share after a 10% tax withholding [5]